Unresolved
We still don’t know whether anyone at this organisation has actually used this technology — zero lived-experience observations exist.
Not yet answered
What are we missing?
HealthAratus Intelligence
GeneSight
GeneSightGeneSight Intelligence
What the accumulated evidence, deployment record and lived experience actually show.
Intelligence lenses
Four ways of interrogating the same reality. Each changes the question, not the subject.
Do published findings about GeneSight match what happens in practice?
Public evidence
New Analysis Published in Peer-reviewed Psychiatry Research Shows Advantages of Combinatorial Algorithm of GeneSight® Psychotropic Test
SignalHunt:validation:Myriad Genetics
What we know · what we don’t
Everything here is open to being corrected by someone who has seen it first-hand.
What we still don’t know
Nobody has answered these yet. Your experience can help us understand what is happening.
Matters of record
Settled elsewhere. Context for reading the above, not something practice can confirm.
- 1 public external signal(s) across 1 source(s).Recorded by HealthAratus
Tool intelligence
What HealthAratus understands
HealthAratus currently understands GeneSight through company records and external market activity.
- Category
- imaging_diagnostics
What HealthAratus is still learning
HealthAratus is beginning to understand GeneSight. As evidence and experience accumulate, what remains unclear will be stated here.
Evidence & claims
What this is built on
The material the questions above were built from, with its attribution.
GeneSight is a pharmacogenomic test that analyzes patient DNA. It identifies how genetic variations may influence individual responses to psychiatric and neurological medications.According to GeneSight
What GeneSight states
The vendor’s own claims. Testable where practice can actually test them.
Stated capability
The test categorizes medications based on their potential for efficacy or increased side effects.
According to GeneSight
Does this change your workflow?
Independent and public evidence
Found in public sources. Not a clinician’s experience, and never presented as one.
Reported outcome
New Analysis Published in Peer-reviewed Psychiatry Research Shows Advantages of Combinatorial Algorithm of GeneSight® Psychotropic Test
Reported publicly
Are you seeing this result?
Company participation
Not yet verified
A record of the reality forming around this technology already exists. No representative of the company has verified participation yet.
Claim your company profileReference
The stable facts, for interpreting everything above.
Overview
What it does
GeneSight is a pharmacogenomic test developed by Myriad Genetics that analyzes a patient's DNA to predict how their genes may affect their response to over 60 psychiatric and neurological medications, including antidepressants, antipsychotics, mood stabilizers, and ADHD treatments.
The test uses a simple cheek swab…
Vendor & external product information, not independently verified by HealthAratus
Where it's used
Deployed in clinic settings
Parent Company
GeneSightvendor
How the reality here has changed
Not enough recorded activity across time yet to describe how the reality here has moved. As accounts of GeneSight accumulate, this becomes a record of how the reality moved rather than a snapshot of one moment.
Connected intelligence
Category intelligence